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Lysosomal degradationrotein A20 is a negative regulator of TNF-induced JNK (c-Jun-N-terminal kinase)
and NFκB (nuclear factor κB) signaling. A20 is an unusual enzyme that contains both ubiquitinating and
deubiquitinating activities. Although A20 is mostly localized in the cytosol, our recent studies reveal that a
fraction of A20 can associate with a lysosome-interacting compartment in a manner that requires its carboxy
terminal zinc ﬁngers, but independent of its ubiquitin modifying activities. Whether the lysosome-associated
A20 has a function in cellular signaling is unclear. Here, we demonstrate that A20 is capable of targeting an
associated signaling molecule such as TRAF2 to the lysosomes for degradation. This process is dependent on
the membrane tethering zinc ﬁnger domains of A20, but does not require A20 ubiquitin modifying activity.
Our ﬁndings suggest a novel mode of A20 action that involves lysosomal targeting of signal molecules bound
to A20.
Published by Elsevier B.V.1. Introduction
Receptors of the proinﬂammatory cytokine TNF (tumor necrosis
factor) superfamily mediate cellular responses to a variety of
environmental stimuli [1,2]. On binding to TNF, TNF receptors
(TNFR) assemble a membrane-associated protein complex comprising
the adaptor protein TRADD (TNF receptor associated death domain), a
Ser/Thr protein kinase RIP1 (receptor interacting protein), and a TRAF
(TNF receptor-associated factor) domain-containing protein TRAF2
[3–8]. Subsequently, a series of intracellular events are induced,
leading to the activation of the transcription factor NFκB. TNF also
activates JNK kinase through TRAF2, which in turn activates another
transcription factor c-Jun [9–11]. The TNFR activation may promote
either cell survival or death depending on the relative output of the
life and death signals associated with these TNFR-activated processes.
The activation of NFκB by TNF induces the expression of many
genes including the zinc ﬁnger protein A20, which turns out to be a
potent inhibitor of TNF signals [12–20]. Genetic ablation of A20 in
mice causes prolonged TNF activation, which is associated with
sustained inﬂammatory responses and cachexia [19]. Thus, A20-
dependent negative regulatory circuit plays a pivotal role in restricting
the intensity and duration of TNF signaling in vivo.Jun-N-terminal kinase; NFκB,
tor; RIP, receptor interacting
mouse embryonic ﬁbroblast
1 301 496 0201.
.V.The mechanism by which A20 regulates TNF signals was proposed
to involve its dual ubiquitin-modifying activities, which can act on a
substrate such as RIP1 to alter its stability. Speciﬁcally, it has been
shown that A20 is capable of removing Lys63-linked ubiquitin chains
from RIP1 using its amino-terminal OTU (ovarian tumor) domain-
dependent deubiquitinating activity. Subsequently, it assembles
Lys48-linked ubiquitin chains on RIP1 using its carboxy terminal
zinc ﬁnger domains to promote the proteasomal degradation of RIP1
[21]. Although downregulation of RIP1 by A20 appears to contribute to
its NFκB inhibitory function [22], many studies demonstrated that A20
mutants lacking ubiquitin-modifying activities can still function and
inhibit TNFα activity under various conditions [15,23–26]. These
observations indicate that additional mechanism(s) may be employed
by A20 to regulate TNF signaling.
In the search for a new mechanism of A20 action, we recently
discovered that a fraction of endogenous and ectopically expressed
A20 is localized to a perinuclear membrane compartment that
interacts dynamically with the lysosomes [26]. This localization
requires the carboxy terminal zinc ﬁnger domains of A20. Coinciden-
tally, the NFκB inhibitory activity of A20 in many cell lines also relies
on these domains [15,23–26]. This correlation suggests that A20 may
be able to target signaling molecules to the lysosomes for degradation,
and therefore regulate the response of cells to TNF signals.
In this report, we demonstrate that A20 can recruit an associated
signaling molecule such as TRAF2 to a lysosome-interacting compart-
ment for degradation. As anticipated, the downregulation of TRAF2
requires the membrane tethering zinc ﬁnger domains of A20.
Interestingly, our results show that A20 dependent downregulation
of endogenous TRAF2 only occurs under certain conditions that
promote TNF-induced apoptosis, suggesting a regulatory role for A20-
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and death during TNF signaling.
2. Materials and methods
2.1. Constructs, antibodies, and chemicals
The pRK-Flag-A20 wt, pRK-HA-A20, pRK-Flag-TRAF2 plasmids and
the plasmid expressing TRAF2ΔRING were described previously
[15,27,28]. The plasmids expressing various A20 mutants were
described previously [26]. The plasmid expressing TRAF2 1-310 was
generated by site directed mutagenesis. The pLNCX2-Flag-TRAF2
plasmid was constructed by ligating the TRAF2 coding sequence into
the XhoI and NotI sites of the pLNCX2 vector (Clontech). The plasmid
expressing CFP-tagged TRAF2 was constructed by ligating the PCR
ampliﬁed TRAF2 coding sequence into the HindIII and KpnI sites of the
pECFP-N1 vector (Clontech). The pEYFP-A20 plasmid was constructed
by ligating the PCR ampliﬁed A20 coding sequence into the BglII and
SalI sites of the pEYFP-C1 vector (Clontech). Flag, Myc, and A20
(59A426) monoclonal antibodies were purchased from Sigma, Roche,
and Imgenex, respectively. Phospho-JNK and JNK antibodies were
purchased from Cell signaling, Inc. The TRAF2 antibody was purchased
from Santa Cruz. Chloroquine and actinomycin D were purchasedFig. 1. A20 induces the degradation of ectopically expressed TRAF2. (A) Downregulation o
expressing plasmid together with the indicated plasmids were analyzed by immunoblottin
except that primary MEF cells were used. (C) As in (A), except that YFP-tagged A20 was als
Immunoﬂuorescence experiment conﬁrms the downregulation of TRAF2 by A20. A clone deri
expressing HA-tagged A20 (HA-A20), and stained with antibodies to visualize the indicated pr
Plan-Neoﬂuar objective (N/A 0.4). Note that the A20 and TRAF2 vesicles were not visible at
expressing cells. The graph shows the quantiﬁcation of the experiment.from Sigma. MG132 was purchased from Calbiochem. TWEAK and
Lysotraker were purchased from Invitrogen.
2.2. Cell lines
293T and COS7 cells were purchased from ATCC, and maintained
according to standard protocols. Wild type and A20 deﬁcient mouse
embryonic cells were kindly provided by Averil Ma (University of
California San Francisco). To make a 293T cell line expressing Flag-
tagged TRAF2, a retroviral packaging cell line (GP2-293) was co-
transfected with pLNCX2-Flag-TRAF2 and a plasmid expressing the
VSV-G protein. The retrovirus-containing medium was collected 72 h
after transfection, and used to infect 293Tcells. TRAF2-expressing cells
were maintained in a medium containing neomycin (500 μg/ml).
Individual clones were selected and analyzed for TRAF2 expression.
2.3. RNA preparation and RT–PCR
Total RNA was extracted using TRIzol reagent (Invitrogen), and
subsequently puriﬁed using an RNeasy MinElute Cleanup kit (QIA-
GEN). For RT–PCR, cDNA was synthesized using the SuperScript™
First-Strand kit (Invitrogen). The following primers were used in PCR
to detect the mRNA expression of mouse A20: forward, 5′-f TRAF2 expression by A20. Detergent extracts of 293T cells transfected with a GFP-
g with antibodies against the indicated proteins. WCE, whole cell extract. (B) As in (A),
o tested and that transfected COS7 cells were directly lysed in the Laemmli buffer. (D)
ved from a single 293T cell stably expressing Flag-TRAF2 was transfected with a plasmid
oteins. The left panel shows an untransfected control. Imageswere obtained using a 20X
this resolution. (E) Pulse chase experiment demonstrates that TRAF2 is unstable in A20
Fig. 2. The RING ﬁnger domain of TRAF2 is required for A20-induced turnover. (A)
Schematic representation of the TRAF2 constructs (Znf, Zinc ﬁnger; CC, coiled-coil;
RING, really interesting gene; TRAF, TNF receptor associated factor). (B) Degradation of
the TRAF2 variants in A20 expressing cells. Numbers underneath the graphs indicate the
relative amount of TRAF2.
Fig. 3. The degradation of TRAF2 in A20-expressing cells is not mediated by the
proteasome. The degradation of TRAF2 in 293T cells expressing wild type A20 was
analyzed by pulse-chase experiment. Where indicated, cells were treated with a
proteasome inhibitor MG132 (20 μM). The graph shows the quantiﬁcation of the
experiment.
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CAATG. Actin was used as a control. Forward, 5′-GCTCCGGCATGTG-
CAA; Reverse, 5′-AGGATCTTCATGAGGTAGT.
2.4. Transfection, immunoblotting, and pulse chase experiments
Transfectionwas done either with Polyfect (Qiagen) for COS7 cells,
or with the TransIT293 reagent (Mirus, Madison, WI) for 293T cells.
Immunoblotting was performed according to standard protocol. Pulse
chase experiments were performed as described previously [29,30].
Brieﬂy, cells were starved in a Met/Cys free medium for 40 min, and
then incubated in a medium containing 35S-Met/Cyc for 20 min. Cells
were then incubated in a chase medium containing excessive amount
of unlabeled Met/Cys. Cell extracts were prepared in a RIPA buffer
(50 mM Tris–HCl pH 7.5, 1% NP40, 0.1% SDS, 0.5% sodium deoxycho-
late, 150 mM sodium chloride, 2 mM EDTA and a protease inhibitor
cocktail). TRAF2 was immunoprecipitated from detergent extracts and
analyzed by SDS–PAGE and autoradiography. To inhibit the lysosome
function, unless otherwise speciﬁed in the ﬁgure legends, 50 mM
NH4Cl or 100 μMchloroquinewas included in the starvation and chase
medium.
2.5. Immunostaining and cell imaging
Immunoﬂuorescence experiments were performed as described
previously [31]. Brieﬂy, cells ﬁxed in a phosphor saline solution (PBS)
containing 4% paraformaldehyde were permeabilized in a solution
containing 0.1% NP40 and 4% normal donkey serum. Cells were then
stained with the primary and secondary antibodies in the same buffer.
Cells were imaged using either a Zeiss Axiovert ﬂuorescence micro-
scope or a Zeiss LSM 510 laser scanning confocal microscope equipped
with a 63X oil immersion Plan-Apochromat objective (N/A 1.4).
3. Results
3.1. A20 induces the degradation of ectopically expressed TRAF2
To test whether A20 was capable of targeting its associated
signaling molecules to the lysosomes for degradation, we investigated
one candidate—the TNF receptor-associated factor 2 (TRAF2) for thefollowing reasons. First, A20 interacts directly with TRAF2 [15].
Second, A20 can block both JNK (Fig. 1A, B) and NFκB activation
[15,17] induced by overexpression of TRAF2. Since TRAF2 over-
expression activates these signaling events via distinct downstream
components [32], a simple explanation of these observations is that
A20 may directly inhibit TRAF2 to terminate these signals. Otherwise,
A20 would have to act on multiple molecules downstream of TRAF2.
We ﬁrst analyzed the effect of A20 overexpression on the steady
state level of TRAF2. 293T cells transfected with a plasmid expressing
Flag-tagged TRAF2 together with either a control or an A20 expressing
plasmid were subjected to extraction by detergent. Immunoblotting
showed that expression of A20 dramatically reduced the TRAF2
protein level (Fig. 1A, lane 4 versus lane 3). This observation was
further conﬁrmed in primary MEF cells (Fig. 1B). In addition,
expression of YFP-tagged A20 in COS7 cells similarly downregulated
TRAF2 (Fig. 1C, lane 3 versus lane 1). Because this experiment was
performed by lysing cells directly in the Laemmli buffer, the loss of
TRAF2 in A20-expressing cells could not be due to partition of TRAF2
into a detergent insoluble fraction. Immunoﬂuorescence experiments
further conﬁrmed that TRAF2 was indeed downregulated in A20-
expressing cells (Fig. 1D).
To test if A20-mediated downregulation of TRAF2 was due to
increased TRAF2 turnover, wemeasured the stability of TRAF2 protein
in a pulse chase experiment. To this end, cells expressing TRAF2 were
radiolabeled with 35S-Met/Cys and subsequently incubated in a chase
medium containing excess unlabeled Met/Cys. The immuno-
precipitation experiment showed that expression of A20 signiﬁcantly
shortened the half life of TRAF2 (Fig. 1E). Together, these results
suggest that A20 can reduce the level of TRAF2 by accelerating its
degradation.
To determine the amino acid sequence in TRAF2 that is important
for A20-dependent degradation, we generated TRAF2 truncation
mutants that lacked either the N-terminal RING domain or the C-
terminal TRAF domain (Fig. 2A). The RING domain of TRAF2 contains
ubiquitin ligase activity that is required for its function in TNF
dependent JNK signaling [32–35]. Interestingly, expression of A20
only had a moderate effect on the half-life of the TRAF2ΔRING mutant
(Fig. 2B, lanes 5–8 versus lanes 1–4). In contrast, a TRAF2 mutant
lacking the TRAF domain (TRAF2 1-310) was destabilized by A20
similarly to wild type TRAF2 (Fig. 2B). Since the TRAF2ΔRING and
Fig. 4. The A20-dependent degradation of TRAF2 requires the membrane tethering activity of A20, but not its ubiquitin-modifying function. (A) Schematic representation of the A20
constructs (OTU, ovarian tumor; NZF, Npl4 zinc ﬁnger). Arrows indicate the location of themutations. (B) The degradation of TRAF2 in 293Tcells expressing the indicated A20 variants
was analyzed by pulse chase experiment. Asterisk indicates a non-speciﬁc protein. (C) Quantiﬁcation of the experiment in (B).
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association of TRAF2with A20 alone is not sufﬁcient to trigger efﬁcient
degradation of TRAF2.
3.2. The degradation of TRAF2 requires the membrane tethering activity
of A20
A previous study showed that A20 contains both ubiquitin ligase
and deubiquitinating activities, which are required for targeting RIP1
to the proteasome for degradation [21]. We therefore tested whether
the ubiquitin proteasome system plays a role in A20-mediated
degradation of TRAF2. Pulse chase experiments showed that the
degradation of TRAF2 in A20-expressing cells was not blocked by
treating these cells with the proteasome inhibitor MG132 (Fig. 3 lanes
5–8). These data argue against the involvement of the proteasome in
this process. To further study this issue, we analyzed TRAF2
degradation in cells expressing A20 mutants defective in either
ubiquitination or deubiquitination. Indeed, both the ubiquitinating
(A20Znf4C2) anddeubiquitinatingdefectiveA20mutants (A20C103A)
were as effective as wild type A20 in downregulating TRAF2 (Fig. 4).
Together, these data strongly indicate that A20 is able to induce TRAF2
turnover by an ubiquitin proteasome independent pathway.
Since we previously found that a fraction of A20 is localized to a
lysosome-associated compartment via its carboxy terminal zinc ﬁnger
domains, we analyzed the degradation of TRAF2 in cells expressingA20 mutants defective in membrane association. Immunoblotting
experiments have shown that these A20 variants were expressed at a
slightly higher level than wild type A20 [26]. Nonetheless, compared
with wild type A20, the A20 mutant lacking the last two zinc ﬁngers
(A20 1-696) was less active, and the A20 mutant lacking the last four
zinc ﬁngers (A20 1-560) was more severely impaired in down-
regulating TRAF2 (Fig. 4). Intriguingly, we previously showed that the
A20 1-696 mutant retained partial interaction with the lysosomes,
whereas the A201-560mutant was exclusively localized to the cytosol
[26]. Thus, the ability of A20 to induce TRAF2 degradation correlates
with its association with the lysosomes. Since A20 mutants defective
in membrane association are also less active in inhibiting NFκB signals
[26], these results suggest that A20 mediated lysosomal degradation
may contribute to its regulation of the TNF signal.
3.3. A20 recruits TRAF2 to a lysosome-associated compartment for
degradation
We next examined the localization of TRAF2 in COS7 cells in the
presence or absence of ectopically expressed A20. When TRAF2 was
expressed alone, it was mostly localized in the cytosol. A fraction of
TRAF2 was associated with membrane vesicles that constantly fused
to form a few large round-shaped vesicles (Figs. 5A–C). The biological
relevance of these vesicles was unclear, but they did not display any
overlapping localization with the lysosomes. In contrast, when A20
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and the remaining TRAF2 was mostly concentrated in a juxtanuclear
region as speckles reminiscent of the A20 staining pattern (Figs. 5D–F)
[26]. Indeed, these TRAF2-containing dots did colocalize precisely
with A20 (Figs. 5G–I), conﬁrming the reported interaction between
A20 and TRAF2 [15]. Consistent with our previous observation that
A20-containing vesicles display dynamic interactions with the
lysosomes [26], the TRAF2-containing vesicles in A20-expressing
cells also overlapped signiﬁcantly with the lysosomes (see insets in
Fig. 5). Thus, A20 is able to recruit TRAF2 to vesicles that are in
association with the lysosomes, which perhaps leads to the degrada-
tion of TRAF2 by a lysosome dependent mechanism.
To test this possibility, 293T cells co-expressing TRAF2 and A20
were treated with two lysosomal inhibitors, ammonium chloride and
chloroquine. The stability of TRAF2 in untreated control cells and the
inhibitor-treated cells were analyzed by pulse chase experiments. Our
data showed that the A20-induced degradation of TRAF2 could be
inhibited by these inhibitors (Figs. 6A, B), conﬁrming the involvement
of the lysosomes in this process.
To see if A20 is required for TRAF2 turnover, we used A20 deﬁcient
primary MEF cells (Fig. 6C). Indeed, ectopically expressed TRAF2 was
stabilized in cells lacking A20. Moreover, expression of A20 in A20
deﬁcient cells completely restored the degradation of TRAF2, resulting
in a lower level of TRAF2 (Fig. 6D). These results further demonstrate
that the stability of ectopically expressed TRAF2 is regulated by A20.Fig. 5. A20 recruits TRAF2 to a lysosome-associated compartment. (A–C) COS7 cells expressing
COS7 cells co-expressing Flag-TRAF2 andHA-A20were stainedwith Lysotracker (red) and an a
Asterisks indicate some examples of TRAF2-containing vesicles that are either colocalized or te
the XZ and YZ axes indicated by the lines. (G–I) COS7 cells co-expressing TRAF2-CFP and YFP-A
confocal microscope.3.4. A20-dependent degradation of endogenous TRAF2
We next examined whether the stability of endogenous TRAF2 is
inﬂuenced by A20. Intriguingly, expression of A20 did not result in
signiﬁcant loss of endogenous TRAF2 protein (data not shown), which
is consistent with a previous report [36]. Moreover, we and others
have found that in cells treatedwith TNFα alone, endogenous TRAF2 is
not degraded [37,38]. On the other hand, endogenous TRAF2 was
found to be rapidly downregulated in MEF cells treated with TNFα
together with actinomycin D, a condition that promotes TNFα-
induced apoptotic signals [39]. Although the degradation of TRAF2
under this condition may be to some extent inﬂuenced by a
proteasome inhibitor and the level of the ubiquitin ligase Siah2,
neither the proteasome inhibitor nor genetic ablation of Siah2
completely stabilizes TRAF2, suggesting that a proteasome indepen-
dent mechanismmay also account for the degradation of TRAF2 under
this condition [39]. We therefore tested whether the lysosomes may
play a role in TRAF2 turnover under this condition and whether the
loss of TRAF2 is dependent on A20. We analyzed the level of
endogenous TRAF2 by immunoblotting and found that it was indeed
decreased in cells treated with TNFα and actinomycin D (Fig. 7A, lanes
1–4). The downregulation of TRAF2 was at least partially dependent
on A20 because the stability of TRAF2 was increased in A20 deﬁcient
MEF cells (Fig. 7A, lanes 5–8 versus lanes 1–4, also see the graph in Fig.
7A). Additionally, pretreating cells with a lysosomal inhibitorFlag-TRAF2were stainedwith Lysotracker (red) and an anti-Flag antibody (green). (D–F)
nti-Flag antibody (green). The insets showamagniﬁed viewof the indicated region (box).
theredwith the lysosomes. The smaller panels in (C) and (F) showvertical sections along
20were ﬁxed and imaged. All imageswere obtainedwith a Zeiss LSM510 laser scanning
Fig. 6. Lysosome dependent degradation of TRAF2 in A20-expressing cells. (A, B) Pulse chase experiments show the inhibition of TRAF2 degradation in A20 expressing cells by
lysosome inhibitors. Graphs show the quantiﬁcation of the experiments. Note that data from two independent experiments for chloroquine treatment (0 and 50 μM) were labeled in
the graph in (B) as dots. Chloroquine at 100 μM appears to reduce the labeling efﬁciency. The lines indicate the average of the two experiments. (C) Characterization of A20 deﬁcient
(A20-/-) MEF cells. A20mRNA level in the indicated cells was determined by RT–PCR. (D) Accumulation of TRAF2 in A20 deﬁcient primary MEF cells. Wild type and A20 deﬁcient MEF
cells were transfected with the indicated plasmids together with Flag-TRAF2 and GFP (transfection efﬁciency control). Whole cell extracts (WCE) were analyzed by immunoblotting.
Shown is a gel representing two independent experiments.
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tion of TRAF2 may take place in the lysosome.
Although TNFα alone is insufﬁcient to activate apoptosis in many
cell lines, a recent study showed that another TNF superfamily
member TWEAK on its own is capable of inducing apoptosis via TNFα
signaling in many types of cancer cells and transformed MEF. TWEAK
can also sensitize these cells to TNFα-induced cell death, and it
appears to act by triggering the degradation of a protein complex
consisting of endogenous TRAF2 via a lysosome dependent mechan-
ism [40]. We therefore tested whether TWEAK-induced TRAF2 loss
requires A20. We ﬁrst conﬁrmed that endogenous TRAF2 could be
downregulated in response to TWEAK treatment and it could be
blocked by the lysosome inhibitor chloroquine, as previously demon-
strated (Fig. 7C, D) [40]. TWEAK-induced TRAF2 loss was also observed
in immortalized wild type MEF cells, but was signiﬁcantly attenuated
in A20 deﬁcient MEF cells (Fig. 7E). Thus, A20 appears to play a role in
TWEAK-induced TRAF2 downregulation.
4. Discussion
Previous work showed that A20 downregulates RIP1 via the
ubiquitin proteasome system. It is thought that both the ubiquitin
ligase and the deubiquitinating activities of A20 are required for RIP1
turnover and for the NFκB inhibitory function of A20 [21]. In thiscontext, it is surprising that we and others found that the ubiquitin
modifying activities of A20 can be dispensable for its function under
many experimental conditions [15,23–26]. Perhaps, there exists an
ubiquitin independent mechanism of A20 action.
In support of this idea, we recently demonstrated that A20 is also
localized to a novel membrane compartment that dynamically
communicates with the lysosomes. Intriguingly, A20 mutants defec-
tive in membrane association also contain reduced NFκB inhibitory
activity, suggesting that A20 may function through this compartment
to participate in cellular signaling [26]. One attractive model is that
A20 may target signaling molecules to this lysosome-associated
compartment for degradation, which may help to regulate the TNF
signaling. However, direct evidence in support of this model has been
lacking.
In this study, we demonstrate that A20 indeed has the capacity to
target an associated signaling molecule such as TRAF2 to the
lysosome-associated compartment for clearance. As expected, the
downregulation of TRAF2 by A20 does not require its ubiquitin
modifying function. Instead, the carboxy terminal zinc ﬁngers of A20
that mediate its membrane association are involved. These results,
together with previous observations that the same zinc ﬁnger
domains are required for A20 function [15, 23–26], indicate that the
membrane associated pool of A20 may be functionally critical for TNF
signaling under certain conditions. Indeed, we showed that
Fig. 7. A20-dependent degradation of endogenous TRAF2. (A) Impaired degradation of endogenous TRAF2 in A20 deﬁcient MEF cells. Wild type (A20+/+) or A20 deﬁcient (A20-/-)
MEF cells were treated with TNFα (40 ng/ml) and actinomysin D (1μg/ml) for the indicated time points. Cell extracts were analyzed by immunoblotting (IB). Graph shows the
quantiﬁcation of four independent experiments. Error bars represent S.D. (n=4). (B) Inhibition of TRAF2 degradation by a lysosomal inhibitor. HeLa cells were treated with TNFα and
actinomysin D for the indicated time periods and analyzed as in (A). Where indicated, cells were pretreated with NH4Cl for 1 h. Numbers indicate the relative level of TRAF2. Shown is
a gel representing 3 independent experiments. (C) TWEAK induces the loss of endogenous TRAF2 by a lysosome dependent mechanism. HeLa cells were treated with the indicated
protein/chemical (TWEAK, 100 ng/ml; chloroquine, 80 μM) for 6 h. Cell extracts were analyzed by immunoblotting. Asterisk indicates a non-speciﬁc band. (D) The speciﬁcity of the
TRAF2 antibody as demonstrated by immunoblotting analyses using whole cell extract from the indicated cell lines. (E) TWEAK-mediated TRAF2 turn over requires A20.
Immortalized wild type (+/+) and A20 knock-out cells were treated for 6 h as indicated. Whole cell extract was subjected to immunoblotting analysis.
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that promotes TNF-induced cell death, and the degradation of TRAF2
can be inhibited by a lysosome inhibitor. Along the same line,
endogenous TRAF2 is also rapidly degraded in many types of cancer
cells in response to TWEAK, another TNF superfamily member, which
on its own is sufﬁcient to induce TNFα dependent cell death [40].
Interestingly, the degradation of TRAF2 under this condition is not
mediated by the ubiquitin proteasome system. Instead, TRAF2 is
targeted to the lysosomes for degradation. We now demonstrate that
TWEAK-mediated loss of TRAF2 is also dependent on A20.
It is likely that TRAF2 may not be the only substrate of A20. An
attractive scenario is that A20-mediated lysosomal degradation of a
collection of signaling molecules required for sustained NFκB and JNK
activation may offer a powerful means to regulate these signaling
activities. In this regard, identiﬁcation of additional substrates that
undergo A20-dependent lysosomal degradation during TNF signaling
would help to further clarify this novel regulatory mechanism in TNF
signaling.
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